Latest Articles

Publication Date
Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer Endpoints News

Published: March 26, 2025, 2:10 p.m.
Slow going: The long journey to diagnosing Endometriosis - NewsBreak: Local News & Alerts

Slow going: The long journey to diagnosing Endometriosis NewsBreak: Local News & Alerts

Published: March 26, 2025, 2:09 p.m.
Slow going: The long journey to diagnosing Endometriosis - newsbreak.com

Slow going: The long journey to diagnosing Endometriosis newsbreak.com

Published: March 26, 2025, 2:09 p.m.
Slow going: The long journey to diagnosing Endometriosis - FOX 17 West Michigan News

Slow going: The long journey to diagnosing Endometriosis FOX 17 West Michigan News

Published: March 26, 2025, 2 p.m.
Endometriosis and the lesser-known thoracic endometriosis syndrome - blogs.bcm.edu

Endometriosis and the lesser-known thoracic endometriosis syndrome blogs.bcm.edu

Published: March 26, 2025, 12:55 p.m.
Endometriosis and the lesser-known thoracic endometriosis syndrome - Baylor College of Medicine | BCM

Endometriosis and the lesser-known thoracic endometriosis syndrome Baylor College of Medicine | BCM

Published: March 26, 2025, 12:55 p.m.
Dissecting Endometriosis: Symptoms, Diagnosis, and Genetic Factors - Yahoo

Dissecting Endometriosis: Symptoms, Diagnosis, and Genetic Factors Yahoo

Published: March 26, 2025, 11:40 a.m.
Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial - Fierce Biotech

Acrivon stops developing Lilly castoff for ovarian and bladder cancers to switch focus to endometrial Fierce Biotech

Published: March 26, 2025, 11:05 a.m.
Living with severe pain - Endometriosis Awareness Month 2025 - Tasmanian Department of Health

Living with severe pain - Endometriosis Awareness Month 2025 Tasmanian Department of Health

Published: March 26, 2025, 10:32 a.m.
Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating - TipRanks

Promising Phase 2 Results for ACR-368 in Endometrial Cancer Justify Buy Rating TipRanks

Published: March 26, 2025, 10:20 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!